Publication | Closed Access

HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats

Cyslt2r AntagonistHami 3379Cell DeathMicroglial InflammationOxidative StressNeuroinflammationInflammationBrain InjuryNeurologyNeuroimmunologyIschemic SyndromeNeuropharmacologyBrain-immune InteractionNeuroprotectionCerebral Blood FlowReperfusion InjuryPharmacologyNeuroscienceMedicine